KDR and nonpapillary renal cell carcinoma: Since VEGF receptor (VEGFR) target therapy is a more conventional therapy for patients with advanced ccRCC, we selected five conventional target therapy agents (sunitinib, sorafenib, axitinib, pazopanib, and rapamycin) and evaluated the responses of the three subtypes.